Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) today reported positive three-month postoperative results from Group 1 patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”). The results validate the Company’s core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.
The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program. Key highlights include positive first-in-human results, a major de-risking milestone, life-changing vision improvements for patients, strong forward momentum with planning for Group 2 surgeries underway, and high confidence from management in the platform.
“These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes,” said Dean Burns, President and CEO of Ocumetics. “Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for Group 2 surgeries.”
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250, levels consistent with legal blindness. Post-implantation outcomes underscore both the clinical effectiveness and real-world impact of the Ocumetics Lens. “All patient outcomes have met safety expectations,” said Dr. Rafael Vázquez, principal investigator of the trial. “From being classified legally blind, my patients can now read, enjoy everyday life activities, and drive. The impact on their independence and sense of freedom has been remarkable.”
The results from Group 1 can be summarized as: safety profile met expectations, visual acuity outcomes met and exceeded expectations, and lens delivery system met expectations. Ocumetics continues to apply its rapid “win-learn” R&D approach, incorporating surgeon feedback to further optimize performance. Based on insights from Group 1, the Company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2.
Manufacturing and testing of optimized lens designs are currently underway. Group 2 surgeries are expected to be scheduled following completion of final lens testing and validation. “Our Group 1 results clearly demonstrated and confirmed the viability of our accommodating intraocular lens technology,” concluded Burns. “This milestone materially strengthens our clinical foundation and positions Ocumetics to build momentum as we advance into Group 2.”
Ocumetics will host an exclusive webinar covering the three-month study results and important updates on its FIH study on Wednesday, February 4, 2026, at 4:00 PM ET. More information is available at www.ocumetics.com/webinar. The Company is a Canadian research and product development company dedicated to developing advanced vision correction solutions. For further information, contact Dave Burwell, Director of Investor Relations, at www.ocumetics.com.
